Patent: 9,555,126
✉ Email this page to a colleague
Summary for Patent: 9,555,126
Title: | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of B-cell malignancies symptoms |
Abstract: | An anti-CD19 maytansinoid immunoconjugate is used for treating B-cell malignancies symptom, in particular Non-Hodgkin\'s lymphoma. |
Inventor(s): | Morariu; Rodica (Paris, FR) |
Assignee: | Sanofi (Paris, FR) |
Application Number: | 14/117,806 |
Patent Claims: | see list of patent claims |
Details for Patent 9,555,126
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2031-05-17 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2031-05-17 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2031-05-17 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |